United States International Trade Commision Rulings And Harmonized Tariff Schedule
faqs.org  Rulings By Number  Rulings By Category  Tariff Numbers
faqs.org > Rulings and Tariffs Home > Rulings By Number > 2005 NY Rulings > NY L80349 - NY L80536 > NY L80523

Previous Ruling Next Ruling
NY L80523




November 8, 2004

CLA-2-21:RR:NC:2:228 L80523

CATEGORY: CLASSIFICATION

TARIFF NO.: 2106.90.9998

Mr. Albert Mendez
Atlas Pharma Corporation
250 Everglade Avenue
Palm Beach, FL 33480

RE: The tariff classification of nutritional supplements from China.

Dear Mr. Mendez:

In your letter dated October 18, 2004, you requested a tariff classification ruling.

The products are vitamins for human consumption, in tablets or capsules. Vitamin B3 (Niacin) is available in either 100 or 500 mg tablets, Vitamin M (Folic Acid) in 400 and 800 mcg tablets, and Lipoic Acid in 100 mg capsules. The vitamins will be imported in hermetically sealed plastic bottles containing 1,000, 5,000, or 10,000 capsules or tablets.

The applicable subheading for the vitamin capsules and tablets will be 2106.90.9998, Harmonized Tariff Schedule of the United States (HTS), which provides for food preparations not elsewhere specified or includedother...otherother. The rate of duty will be 6.4 percent ad valorem.

This merchandise is subject to The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which is regulated by the Food and Drug Administration (FDA). Information on the Bioterrorism Act can be obtained by calling FDA at telephone number (301) 575-0156, or at the Web site www.fda.gov/oc/bioterrorism/bioact.html.

This ruling is being issued under the provisions of Part 177 of the Customs Regulations (19 C.F.R. 177).

A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, contact National Import Specialist Stanley Hopard at 646-733-3029.

Sincerely,

Robert B. Swierupski
Director,

Previous Ruling Next Ruling

See also: